anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Human papillomavirus (HPV) is a sexually transmitted virus, which infects approximately 80% of all men and women at some time in their lives. Usually, the infection is resolved successfully by the body's immune system. Persistent infection with high-risk HPV (hrHPV) is necessary but not sufficient for cervical cancer development, and additional factors, such as the vaginal microbiome (vaginome), are thought to be involved. The aim of this study is to investigate whether either vaginal dysbiosis (imbalance in vaginal bacterial composition) or sexually transmitted pathogens, e.g., Chlamydia trachomatis (CT), are possible cofactors for hrHPV infection and HPV-induced cervical dysplasia in asymptomatic women attending the Dutch Cervical Cancer Screening Program. In this study, 492 hrHPV-positive and 500 hrHPV-negative cervical smears from women attending the Screening Program were included. Age and cytology were known for the hrHPV-positive samples. All cervical smears were diluted in Aptima® specimen transfer medium and tested with Aptima® transcription-mediated amplification assays targeting CT, Neisseria gonorrhoeae (NG), Mycoplasma genitalium (MG), Candida spp. (CS), C. glabrata (CG), Trichomonas vaginalis (TV), and bacterial vaginosis (BV). The prevalences of CT, NG, MG, CS, CG, TV, and BV in this cohort were found to be 1.9%, 0.0%, 1.7%, 5.4%, 1.4%, 0.1%, and 27.2%, respectively. When comparing HPV groups, it was found that CT, MG, and BV had a significantly higher prevalence in hrHPV-positive smears as compared with hrHPV-negative samples (for all p < 0.001). No significant differences were found when comparing different age groups and cytology outcomes. In conclusion, vaginal dysbiosis seems associated with hrHPV infection in women attending the Dutch Cervical Cancer Screening Program.
A normal hygiene kit will be distributed to the households. In addition, a mirror will be added to see the impact of having a mirror by the handwashing stand on handwashing behaviour. The mirror will have a plastic edge and be 30x 50cm in size.
PURPOSE:A vaccine for animals comprising an oily adjuvant using both a surface active agent and liquid paraffin. CONSTITUTION:A hydrophilic oily adjuvant of water-in-oil type obtained by blending anhydrous mannitol oleic ester (molecular weight: 428, elemental ratio of C:H:O=24:44:6), a surface active agent sown by the formula, with liquid paraffin in the ratio of 1:9 is used to give a vaccine for animals. The amount of an antigen (stock solution of vaccine) to be blended wit the adjuvant is preferably 30% antigen based on 70% adjuvant. EFFECT:Only a small amount of stock solution of vaccine is used and the vaccine can be rationally produced. The viscosity of AMOE adjuvant has 1/50 the viscosity of existing Freund's adjuvant and the vaccine is extremely readily processed into emulsion and injection. The vaccine will not change for a long period (>=one year) and maintains a good emulsified state. The vaccine is observed to have significant difference in terms of rise in antibody titer and sustained release compared with other vaccines.
Ectosomes are carriers of proangiogenic factors during cancer progression. This study investigated whether the proangiogenic effect exerted by melanoma-derived ectosomes on recipient endothelial cells is mediated by ectosomal αvβ3 and αvβ5 integrins. Ectosomes were isolated from the conditioned culture media of four melanoma cell lines and melanocytes. Changes in gene and protein expression of αvβ3 and αvβ5 integrins, as well as VEGF and TNF-α were assessed in ectosome-treated endothelial cells. To confirm the functional involvement of ectosomal integrins in functional tests (Alamar Blue, wound healing and tube formation assays), ectosomes were also pretreated with anti-integrin antibodies and integrin-blocking peptides echistatin and cilengitide. Melanoma-derived ectosomes induced changes in the expression of αvβ3 and αvβ5 integrins in recipient endothelial cells, leading to increased viability, migratory properties, and tube formation potential. The extent of proangiogenic stimulation varied depending on the types of cells releasing ectosomes and the recipient cells. The use of anti-integrin antibodies and integrin-blocking peptides revealed a more significant role for the αvβ5 integrin/VEGF than the αvβ3 integrin/TNF-α pathway in the interactions between ectosomes and endothelial cells. The study demonstrated the functional role of ectosomal αvβ3 and αvβ5 integrins. It also provided a baseline understanding of ectosome-mediated αvβ3 integrin/TNF-α and αvβ5 integrin/VEGF signaling in angiogenesis.
The invention discloses a method of treatment for drug addiction, comprising administering a therapeutic agent to a patient. The therapeutic agent is delivered in an inactive state and is converted into its active form in the presence of a narcotic. The conversion produces at least one unpleasant side effect for the patient. The therapeutic agent is implanted in the form of a depot, and maybe a prodrug or microspheres. The agent may be injectable or may be packaged in the form of bioerodible sticks. The agent may also be delivered via a surgical method. The disclosed method can also be used to detect the consumption of a banned substance.
Dosing and initial route of therapy (that is, IV or oral) for cUTI or pyelonephritis should be determined by the severity of the infection. CIPRO should be administered as described in Table 3. Administer CIPRO for Oral Suspension using the co-packaged graduated spoon [see Dosage and Administration (2.7)].

1 The total duration of therapy for cUTI and pyelonephritis in the clinical trial was determined by the physician. The mean duration of treatment was 11 days (range 10 to 21 days).

2Begin drug administration as soon as possible after suspected or confirmed exposure. 

3Begin drug administration as soon as possible after suspected or confirmed exposure to Y. pestis.
Inventors have generated two human anti-cath-D scFv fragments cloned in the human IgG1λ format (F1 and E2) that efficiently bind to human and mouse cath-D, even at the acidic pH of the TNBC microenvironment. F1 and E2 accumulated in TNBC MDAMB-231 tumor xenografts, inhibited tumor growth and improved mice survival without apparent toxicity. Using this xenograft model, they found that the Fc function of F1 was essential for maximal tumor inhibition. Inventors have shown that the anti-cath-D antibody F1 treatment prevented the recruitment of tumor-associated macrophages and myeloid-derived suppressor cells within the tumor, a specific effect associated with a less immunosuppressive tumor microenvironment. Moreover F1 inhibited tumor growth of TNBC patient-derived xenografts (PDXs). This preclinical proof-of-concept study validates the feasibility and efficacy of an immunomodulatory antibody-based strategy against cath-D to treat patients with TNBC. Accordingly, the present invention relates to an anti-cath-D antibody which inhibits the tumor recruitment of immunosuppressive tumor-associated macrophages M2 and myeloid-derived suppressor cells for use in the treatment of cancer.
Tamsulosin 0.2 mg taken orally once daily and finasteride-matching placebo taken orally once daily for 12 months. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
Eligible patients will be randomized to either conventional surgery or stereotactic radiosurgery, or participate as a separate group of the study, if they refuse randomization. At the time of diagnosis, patients may be given dexamethasone which will be continued throughout treatment then discontinued in a tapered fashion. Patients with supratentorial tumors and a history of seizures may be treated with anticonvulsants. For patients in the surgical group, surgery will be performed using standard techniques and any necessary intraoperative adjuncts. For patients in the stereotactic radiosurgery group, stereotactic radiosurgery will be delivered using the modified linear accelerator and multiple non-coplanar converging arcs. The dose prescribed will be dependent on the volume treated. Changes in patients' clinical courses will be treated as medically necessary. Should metastases recur or progress at the primary intracerebral site or at a distant intracerebral site, patients who received radiosurgery remain eligible for surgical resection and patients who received conventional surgery may undergo repeat resection or radiosurgery. Whole brain radiotherapy may be given to patients who demonstrate local or distant recurrence and can be given as the primary therapy or as adjunctive therapy. The WBRT dose will be 30 Gy delivered in ten fractions.
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic kidney disease with high phenotypic variability. Furthering insights into patients' ADPKD progression could lead to earlier detection, management, and alter the course to end stage kidney disease (ESKD). We sought to identify patients with rapid decline (RD) in kidney function and to determine clinical factors associated with RD using a data-driven approach. A retrospective cohort study was performed among patients with incident ADPKD (1/1/2002-12/31/2018). Latent class mixed models were used to identify RD patients using differences in eGFR trajectories over time. Predictors of RD were selected based on agreements among feature selection methods, including logistic, regularized, and random forest modeling. The final model was built on the selected predictors and clinically relevant covariates. Among 1,744 patients with incident ADPKD, 125 (7%) were identified as RD. Feature selection included 42 clinical measurements for adaptation with multiple imputations; mean (SD) eGFR was 85.2 (47.3) and 72.9 (34.4) in the RD and non-RD groups, respectively. Multiple imputed datasets identified variables as important features to distinguish RD and non-RD groups with the final prediction model determined as a balance between area under the curve (AUC) and clinical relevance which included 6 predictors: age, sex, hypertension, cerebrovascular disease, hemoglobin, and proteinuria. Results showed 72%-sensitivity, 70%-specificity, 70%-accuracy, and 0.77-AUC in identifying RD. 5-year ESKD rates were 38% and 7% among RD and non-RD groups, respectively. Using real-world routine clinical data among patients with incident ADPKD, we observed that six variables highly predicted RD in kidney function.
PURPOSE:To prepare the title make-up having excellent feeling, moisture-retension, perfume-retension, etc., by forming a composition containing silk powder, wool powder, cosmetic powder base and an oily substance as effective components, to powdery or cake form. CONSTITUTION:Silk powder and wool powder (which passes through the 60 mesh Tyler standard sieve) is mixed to an aqueous emulsion of a cosmetic powder base (e.g. titanium oxide, etc.) and an oily substance, and the emulsion is demulsified by adding a water-miscible organic solvent (e.g. methanol, etc.) to the emulsion under stirring. The solid component is separated from the demulsified product, and dried to obtain the objective make-up. It consists of a powdery substance uniformly and stably coated with the oily substance, adheres to the skin easily without using water, and has excellent detachability from a powder puff, spreadability, and applicability to the powdered skin.
Intervention: Dolor-X Hot Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
Infuse LEMTRADA over 4 hours starting within 8 hours after dilution. Extend the duration of the infusion if clinically indicated.

Administer LEMTRADA in a setting in which equipment and personnel to appropriately manage anaphylaxis, serious infusion reactions, myocardial ischemia, myocardial infarction, and cerebrovascular and respiratory adverse reactions are available [see Warnings and Precautions (5.2)]. 

Do not add or simultaneously infuse other drug substances through the same intravenous line. Do not administer as an intravenous push or bolus.

Obtain a baseline ECG. Monitor vital signs before the infusion and periodically during the infusion. Provide appropriate symptomatic treatment for infusion reactions as needed. Consider immediate discontinuation of the intravenous infusion if severe infusion reactions occur.

Observe patients for infusion reactions during and for at least 2 hours after each LEMTRADA infusion. Consider longer periods of observation if clinically indicated. Inform patients that they should report symptoms that occur during and after each infusion because they may indicate a need for prompt medical intervention [see Warnings and Precautions (5.2)].
Participants randomized to this intervention will receive 24 weeks of nicotine patches and nicotine mini-lozenges, starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 20 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 22 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges. Participants randomized to this intervention will receive a brief (15-30 minute) phone or video counseling session 1 week prior to the TQD to promote engagement with free mobile health resources and then a brief (10-20 minute) follow-up phone or video session during the first week post-TQD to mimic a nurse or clinician follow-up after a quit attempt.
Pharmaceutical device for placing between the eyelid and the eyeball comprises a lamellar mass (A) of plasticised agar or medical-grade nitrocellulose in which is dispersed >=1 active ingredient (I) capable of diffusing through (A). (A) is supple, insoluble in tear fluid and physiologically inert. Pref. (A) is a central structure held between 2 other lamellae (B) of the same material but which contain no (I) or less of it than (A). Used for sustained delivery of (I), e.g. antibiotics, hormones, myotics, local anaesthetics, antivirals, anti-inflammatories or vasoconstrictors, to the eye. Unlike other polymers proposed agar and nitrocellulose are easily sterilised without altering their structures and require no special precautions for their preservation. By adjusting the conditions of prodn. the coefft. of swelling can be regulated to ensure that the device remains in its correct posn.
B-mode grayscale images will be used by ultrasound to assess peripheral lung lesions. Information including size, location, and intercostal chest wall thickness will be collected. Then, Investigators will use transthoracic 2D-SWE to assess those lesions.

Investigators intend to use regions of interest (ROIs) with 3-mm diameter, and select up to four ROIs with the highest mean elasticity values. the average as the final value will be calculated. If patients had multiple sub-pleural lung lesions, the largest and the most approachable one will be chosen to perform 2D-SWE. Final diagnosis will be made via appropriate diagnostic modalities including computed tomography of chest, microbiological results and guided biopsies if indicated.
PURPOSE: A coronary artery analyzing apparatus is provided to discover the cardiovascular disease in advance by measuring a blood flow, a blood flow resistance, and a blood flow speed. CONSTITUTION: A bio signal measuring system(100) is composed of a bio signal measuring sensor part(120), a bio signal receiving and processing part(140). The bio signal measuring sensor part comprises an electrocardiogram sensor(122), a phonocardiogram sensor(124), and a pulse wave sensor(126). The bio signal receiving and processing part are connected to each sensor of the bio signal measuring sensor part, receives the measured bio signal, and processes a signal processing. An analysis index calculating system(200) comprises a main processor(210). A main processor is connected to the bio signal receiving and processing part. The processor receives the measured data and produces biomechanical index for analyzing cardiovascular.
Prior research has highlighted the therapeutic benefits of acute intermittent hypoxia (AIH) in enhancing motor performance after motor incomplete spinal cord injury and in able-bodied individuals. Although studies in rodents and humans indicate that AIH may facilitate motor excitability, the relationship between excitability changes and functional performance remains unclear. In addition, discrepancies in the effects of AIH on excitability in able-bodied individuals merit further investigation. Understanding the concurrent impact of repetitive AIH on voluntary activation and spinal reflex excitability may clarify the functional implications of AIH for muscle force production. High voluntary activation is vital for sustaining torque production during activities that require repeated muscle contractions. We hypothesized that repetitive AIH would attenuate decreases in both voluntary activation and maximum torque production typically observed during fatiguing contractions. To test this hypothesis, we examined the effects of four consecutive days of AIH on voluntary activation and torque generation during repeated maximal plantar flexion contractions. We assessed changes in voluntary activation using the central activation ratio by calculating the ratio of voluntary torque to the torque produced with supramaximal electrical stimulation. Consistent with our hypothesis, we show that repetitive AIH significantly increases both voluntary activation and peak torque during fatiguing contractions. We did not observe any changes in resting spinal reflex excitability or antagonist muscle coactivation during fatiguing contractions post-AIH. Together, these findings suggest that repetitive AIH reduces performance fatigability through enhanced descending neural drive. Optimizing voluntary activation is critical for facilitating the recovery of functional walking skills after neurological injury.NEW & NOTEWORTHY This study shows that repetitive acute intermittent hypoxia (AIH) significantly increases both voluntary activation and peak torque during fatiguing lower limb contractions. However, resting spinal reflex excitability and antagonist muscle coactivation during fatiguing contractions did not change following repetitive AIH. Together, these observations indicate that repetitive AIH reduces performance fatigability through enhanced descending neural drive. These findings underscore the therapeutic potential of AIH for promoting motor recovery after neurological injury.
Standard education group will be carried out at discharge, discharge orientation of the patient with diabetes and application of the Diabetes Self-Care Activity Questionnaire (QAD). For this group, a new contact will be made within 30 days after discharge, where the QAD will be applied again.
We experienced cases of malnutrition and vitamin B1 deficiency after gastrointestinal cancer surgery, but they had a good course after vitamin B1 administration. Case 1 is a woman in her 70s who underwent laparoscopic distal gastrectomy for gastric cancer 2 months ago. While under outpatient observation, she was found collapsed at home and urgently brought to the hospital. She lost 3 kg of body weight in 2 weeks and was able to take in oral intake by giving fluids for malnutrition, but was unable to sit up unaided. During the course of hospitalization, vitamin B1 deficiency was reported, and vitamin B1 administration was started, which enabled her to walk independently. Case 2 is a man in her 50s who underwent video-assisted thoracic esophagectomy for esophageal cancer approximately 1 year ago. He was urgently brought to the hospital due to decreased oral intake due to alcohol dependence. 17.1 kg/m2 BMI, malnutrition, 67/40 mmHg blood pressure, and decreased left ventricular septal wall motion were observed. Vitamin B1 deficiency due to alcohol dependence was suspected, so vitamin B1 administration was started, and blood pressure increased within a few hours.
Interest in analyzing recurrent event data has increased over the past few decades. One essential aspect of a risk prediction model for recurrent event data is to accurately distinguish individuals with different risks of developing a recurrent event. Although the concordance index (C-index) effectively evaluates the overall discriminative ability of a regression model for recurrent event data, a local measure is also desirable to capture dynamic performance of the regression model over time. Therefore, in this study, we propose a time-dependent C-index measure for inferring the model's discriminative ability locally. We formulated the C-index as a function of time using a flexible parametric model and constructed a concordance-based likelihood for estimation and inference. We adapted a perturbation-resampling procedure for variance estimation. Extensive simulations were conducted to investigate the proposed time-dependent C-index's finite-sample performance and estimation procedure. We applied the time-dependent C-index to three regression models of a study of re-hospitalization in patients with colorectal cancer to evaluate the models' discriminative capability.
Women participating in the trial will receive a spinal cord stimulator (SCS). Women will first undergo a trial implantation period of 14 days. When the trial period is considered successfull (at least 50 percent reported pain reduction) women will receive definitive placement of the SCS. Normal lead placement( bilateral TH8-12) and different stimulation types will be used (FAST, subthresholdand/orCombination). When participating in the trial, women will be asked to complete a set of questionnaires on several occasions, i.e. at baseline, 3 months after implantation, 6 months after implantation and 12 months after implantation.
Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred in patients treated with 5-HT1 agonists, and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the 5-HT1 agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine when they were not. Also, patients with migraine may be at increased risk of certain cerebrovascular events (e.g., stroke, hemorrhage, TIA). Discontinue ZEMBRACE SymTouch injection if a cerebrovascular event occurs.

Before treating headaches in patients not previously diagnosed with migraine or in patients who present with atypical symptoms, exclude other potentially serious neurological conditions. ZEMBRACE SymTouch injection is contraindicated in patients with a history of stroke or TIA.
Caregivers receive access to the CONNECT tool, watch an educational video on self care and receive a personalized list of resources based on caregiver preferences. Caregivers also receive access to and complete at least 2 calls, at baseline and at week 4, with a caregiver navigator to review the resource list and address any additional needs.
Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG\>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.